{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:49:17Z","timestamp":1775486957632,"version":"3.50.1"},"reference-count":24,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec><jats:title>Background\/aims<\/jats:title><jats:p>There is a paucity of high-level evidence to support the management of childhood uveitis, particularly for those children without juvenile idiopathic arthritis uveitis (JIA). We undertook a modified Delphi consensus exercise to identify agreement in the management of chronic anterior uveitis (CAU), the most common manifestation of childhood disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A four-round, two-panel process was undertaken between June and December 2017. Paediatric uveitis specialists identified through multiple sources, including a multicentre network (the Paediatric Ocular Inflammation Group), were invited to participate. They were asked whether they agreed with items derived from existing guidelines on the management of JIA-U when extrapolated to the population of all children with CAU. Consensus was defined as agreement greater than or equal to 75% of respondents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>26 of the 38 (68%) invited specialists participated with the exercise, and response rates were 100% for rounds one to three, and 92% for round four. Consensus was reached on 23 of the 44 items. Items for which consensus was not reached included management at presentation, use of systemic and periocular steroids for children with severe disease and the role of conventional steroid sparing immunosuppressants beyond methotrexate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The areas of management uncertainty at the level of the group, as indicated by absence of consensus, reflect the areas where the evidence base is particularly poor. Our findings identify the key areas for the future research needed to ensure better outcomes for this blinding childhood ocular inflammatory disorders.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2018-313789","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T21:15:39Z","timestamp":1556831739000},"page":"11-16","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK"],"prefix":"10.1136","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8933-5864","authenticated-orcid":false,"given":"Ameenat Lola","family":"Solebo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jugnoo S","family":"Rahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D","family":"Dick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athimalaipet V","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive","family":"Edelsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"2020042817383307000_104.1.11.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)02148-7"},{"key":"2020042817383307000_104.1.11.2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2000.078001084.x"},{"key":"2020042817383307000_104.1.11.3","first-page":"1","article-title":"The challenge of pediatric uveitis: tertiary referral center experience in the United States","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"2020042817383307000_104.1.11.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.11.009"},{"key":"2020042817383307000_104.1.11.5","first-page":"92","article-title":"Uveitis in juvenile idiopathic arthritis","volume":"112","year":"2015"},{"key":"2020042817383307000_104.1.11.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.07.052"},{"key":"2020042817383307000_104.1.11.7","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.7.879"},{"key":"2020042817383307000_104.1.11.8","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/acr.23224","article-title":"Impact of uveitis on quality of life in adult patients with juvenile idiopathic arthritis","volume":"69","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2020042817383307000_104.1.11.9","article-title":"Impact of juvenile idiopathic arthritis associated uveitis in early adulthood","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"2020042817383307000_104.1.11.10","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (sycamore trial)","volume":"15","year":"2014","journal-title":"Trials"},{"key":"2020042817383307000_104.1.11.11","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.22613","article-title":"Uveitis events during adalimumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the biologics in Pediatric Rheumatology registry","volume":"67","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2020042817383307000_104.1.11.12","year":"2007","journal-title":"The Delphi technique: making sense of consensus"},{"key":"2020042817383307000_104.1.11.13","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.160069"},{"key":"2020042817383307000_104.1.11.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2126-1"},{"key":"2020042817383307000_104.1.11.15","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2013.800561"},{"key":"2020042817383307000_104.1.11.16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00296-015-3231-3","article-title":"Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus","volume":"35","year":"2015","journal-title":"Rheumatol Int"},{"key":"2020042817383307000_104.1.11.17","article-title":"Outcome measures in paediatric uveitis interventional studies"},{"key":"2020042817383307000_104.1.11.18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.arthro.2017.11.022","article-title":"Expert opinion is necessary: Delphi panel methodology facilitates a scientific approach to consensus","volume":"34","year":"2018","journal-title":"Arthroscopy"},{"key":"2020042817383307000_104.1.11.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213131"},{"key":"2020042817383307000_104.1.11.20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/acr.23610","article-title":"Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis","volume":"71","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2020042817383307000_104.1.11.21","article-title":"Clinical Commissioning Policy: Adalimumab (Humira) and Infliximab (Remicade) as Anti-TNF Alpha Treatment Options for Paediatric Patients with Severe Refractory Uveitis. NHS England D12\/P\/a","year":"2018"},{"key":"2020042817383307000_104.1.11.22","article-title":"Beh\u00e7et's disease in children, an overview","volume":"14","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"2020042817383307000_104.1.11.23","doi-asserted-by":"publisher","DOI":"10.1080\/08035250310007213"},{"key":"2020042817383307000_104.1.11.24","article-title":"A phase II trial protocol of tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the aptitude trial)","volume":"2","year":"2018","journal-title":"BMC Rheumatol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2018-313789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:59:37Z","timestamp":1601110777000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2018-313789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12,12]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1136\/bjophthalmol-2018-313789"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313789","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]}}}